(2017) Cardiovascular safety and benefits of GLP-1 receptor agonists
For patients with an A1C of 6.5% to 7.5%, metformin is the preferred initial agent, with GLP-1 receptor agonists, dipeptidyl-peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), or an alpha-glucosidase inhibitor listed as viable alternatives
Unlike standard GLP-1 treatments, which often use higher doses for significant weight loss, microdosing involves consistently taking lower doses
This procedure is especially beneficial for patients who experience loose abdominal skin or muscle separation after significant weight loss
In addition, recent clinical evidence from the AngioSafe T2DM Study demonstrated no association between GLP-1 RAs and severe diabetic retinopathy [107], suggesting that GLP-1 RA does not have a causal influence on retinopathy independent of glucose lowering
Why some researchers prefer the thigh Thigh injections produce a slightly slower, more gradual absorption curve compared to the abdomen